With an arsenal of antibody assets based on IgE, IgA, and IgG, the newly combined company has opportunities across cancer indications.

Converging computational and laboratory technologies are helping anti-cancer immune responses hit their target more effectively.

In the landmark Amgen v. Sanofi case (previously covered here), the Supreme Court affirmed that patent claims drawn to a genus of ...

Antibody-drug conjugates and their development remains a central theme in ongoing research within the realm of ovarian cancer ...

Automation and machine learning are transforming antibody discovery at LabGenius, with the EVA™ platform enabling rapid, high ...

As of January 31st, 2025, we held $12.9 million in cash compared to $3.5 million at the fiscal year-end 2024. This increase was driven by the successful execution of our ATM program, through which we ...

Her expertise is in personal finance and investing, and real estate. Morsa Images / Getty Images Sequence risk is the danger that the timing of withdrawals from a retirement account will have a ...

Guangdong Provincial Key Laboratory of Advanced Biomaterials, Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen 518055, China ...

Next generation sequencing technology has the capability to identify ... This discovery has the potential to develop vaccines that increase B cell mutation to develop antibodies for hard-to-treat ...

"Participants took the Baycrest Tour, which resembles an audio-guided museum tour, followed by tests assessing memory for details (e.g., the color of a painting) or sequences (e.g., whether a ...